Log In
Print
BCIQ
Print
Print this Print this
 

salmeterol/fluticasone (AirFluSal Forspiro, IrFlosol Forspiro) (formerly VR315)

  Manage Alerts
Collapse Summary General Information
Company Vectura Group plc
DescriptionCombination of salmeterol, a long-acting adrenergic receptor beta 2 agonist (LABA), and fluticasone, an inhaled corticosteroid, that uses Vectura's GyroHaler dry powder inhaler
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic ModalitySmall molecule: Combination

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$45.0M

$10.0M

$35.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today